Active immunization of humans with dendritic cells - PubMed (original) (raw)

Review

Active immunization of humans with dendritic cells

M V Dhodapkar et al. J Clin Immunol. 2000 May.

Abstract

Dendritic cells (DCs) are potent antigen-presenting cells specialized to initiate T-cell immunity. The development of methods to generate large numbers of DCs has facilitated their application for immunotherapy. Recent studies have demonstrated the safety and immunogenicity of DCs in humans and have begun to outline the durability, kinetics, and nature of the elicited T-cell responses. However, DC-based immunotherapy remains a challenge and several parameters need to be examined to optimize immune responses, in order to maximize clinical efficacy against cancer and infectious diseases.

PubMed Disclaimer

Similar articles

• Mutual helper effect in copulsing of dendritic cells with 2 antigens: a novel approach for improvement of dendritic-based vaccine efficacy against tumors and infectious diseases simultaneously.
  Shojaeian J, Jeddi-Tehrani M, Dokouhaki P, Mahmoudi AR, Ghods R, Bozorgmehr M, Nikoo S, Bayat AA, Akhondi MM, Ostadkarampour M, Rezania S, Zarnani AH. Shojaeian J, et al. J Immunother. 2009 May;32(4):325-32. doi: 10.1097/CJI.0b013e31819aa31e. J Immunother. 2009. PMID: 19342973
• Enhanced priming of antigen-specific CTLs in vivo by embryonic stem cell-derived dendritic cells expressing chemokine along with antigenic protein: application to antitumor vaccination.
  Matsuyoshi H, Senju S, Hirata S, Yoshitake Y, Uemura Y, Nishimura Y. Matsuyoshi H, et al. J Immunol. 2004 Jan 15;172(2):776-86. doi: 10.4049/jimmunol.172.2.776. J Immunol. 2004. PMID: 14707047
• Day 3 Poly (I:C)-activated dendritic cells generated in CellGro for use in cancer immunotherapy trials are fully comparable to standard Day 5 DCs.
  Truxova I, Pokorna K, Kloudova K, Partlova S, Spisek R, Fucikova J. Truxova I, et al. Immunol Lett. 2014 Jul;160(1):39-49. doi: 10.1016/j.imlet.2014.03.010. Epub 2014 Apr 12. Immunol Lett. 2014. PMID: 24726860
• Immunotherapy exploiting the versatility of dendritic cells.
  Kadowaki N. Kadowaki N. Ther Apher Dial. 2003 Jun;7(3):312-7. doi: 10.1046/j.1526-0968.2003.00048.x. Ther Apher Dial. 2003. PMID: 12924606 Review.
• Dendritic cells as vectors for immunotherapy of cancer.
  Paczesny S, Ueno H, Fay J, Banchereau J, Palucka AK. Paczesny S, et al. Semin Cancer Biol. 2003 Dec;13(6):439-47. doi: 10.1016/j.semcancer.2003.09.008. Semin Cancer Biol. 2003. PMID: 15001163 Review.

Cited by

• Active specific immunotherapy targeting the Wilms' tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trials.
  Van Driessche A, Berneman ZN, Van Tendeloo VF. Van Driessche A, et al. Oncologist. 2012;17(2):250-9. doi: 10.1634/theoncologist.2011-0240. Epub 2012 Jan 30. Oncologist. 2012. PMID: 22291091 Free PMC article. Review.
• A double-blind randomized phase I clinical trial targeting ALVAC-HIV vaccine to human dendritic cells.
  Eller MA, Slike BM, Cox JH, Lesho E, Wang Z, Currier JR, Darden JM, Polonis VR, Vahey MT, Peel S, Robb ML, Michael NL, Marovich MA. Eller MA, et al. PLoS One. 2011;6(9):e24254. doi: 10.1371/journal.pone.0024254. Epub 2011 Sep 16. PLoS One. 2011. PMID: 21949699 Free PMC article. Clinical Trial.
• Efficient in vitro expansion of JC virus-specific CD8(+) T-cell responses by JCV peptide-stimulated dendritic cells from patients with progressive multifocal leukoencephalopathy.
  Marzocchetti A, Lima M, Tompkins T, Kavanagh DG, Gandhi RT, O'Neill DW, Bhardwaj N, Koralnik IJ. Marzocchetti A, et al. Virology. 2009 Jan 20;383(2):173-7. doi: 10.1016/j.virol.2008.10.046. Epub 2008 Dec 5. Virology. 2009. PMID: 19062062 Free PMC article.
• Dendritic cells pulsed with gp96-peptide complexes derived from human hepatocellular carcinoma (HCC) induce specific cytotoxic T lymphocytes.
  Wang XH, Qin Y, Hu MH, Xie Y. Wang XH, et al. Cancer Immunol Immunother. 2005 Oct;54(10):971-80. doi: 10.1007/s00262-005-0662-9. Epub 2005 Jun 18. Cancer Immunol Immunother. 2005. PMID: 15965645 Free PMC article.
• Cancer vaccine development: protein transfer of membrane-anchored cytokines and immunostimulatory molecules.
  Cimino AM, Palaniswami P, Kim AC, Selvaraj P. Cimino AM, et al. Immunol Res. 2004;29(1-3):231-40. doi: 10.1385/IR:29:1-3:231. Immunol Res. 2004. PMID: 15181285 Review.

References

1. 1. Science. 1999 May 21;284(5418):1351-4 - PubMed
2. 1. Cancer Immunol Immunother. 1999 May-Jun;48(2-3):118-22 - PubMed
3. 1. J Leukoc Biol. 1999 Nov;66(5):698-704 - PubMed
4. 1. J Cell Biol. 1999 Nov 1;147(3):599-610 - PubMed
5. 1. Hum Immunol. 1999 Jul;60(7):562-7 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.

• Other Literature Sources

  • The Lens - Patent Citations

• Medical

  • MedlinePlus Health Information